1
Country: USA | Funding: $936M
Strive Health is a provider of care delivery models aimed at improving chronic kidney disease care.
Strive Health is a provider of care delivery models aimed at improving chronic kidney disease care.
2
Country: USA | Funding: $646M
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines.
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines.
3
Country: USA | Funding: $624M
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
4
Country: USA | Funding: $555.1M
Monogram Health is a nephrologists to deliver transformative kidney care services.
Monogram Health is a nephrologists to deliver transformative kidney care services.
5
Country: USA | Funding: $442.5M
Akebia Therapeutics develops treatments for ischemia and vascular diseases. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Pursuing a new standard of care for patients with anemia associated with chronic kidney disease (CKD)
Akebia Therapeutics develops treatments for ischemia and vascular diseases. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Pursuing a new standard of care for patients with anemia associated with chronic kidney disease (CKD)
6
Country: UK | Funding: $411.7M
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
7
Country: USA | Funding: $266M
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
8
Country: Sweden | Funding: $210.4M
Calliditas Therapeutics, a specialty pharmaceutical company that develops pharmaceutical products in fields of unmet medical need. Its products include Nefecon, a treatment for IgA nephropathy and Busulipo, an alternative for myeloablation prior to bone marrow transplantation.
Calliditas Therapeutics, a specialty pharmaceutical company that develops pharmaceutical products in fields of unmet medical need. Its products include Nefecon, a treatment for IgA nephropathy and Busulipo, an alternative for myeloablation prior to bone marrow transplantation.
9
Country: USA | Funding: $198.8M
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
10
Country: UK | Funding: $193.7M
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).
11
Country: Israel | Funding: $185M
Healthy.io de Dip.io, a home-based urinalysis kit that turns a smartphone into a clinical-grade diagnostic device. It’s the first smartphone-based urine test to secure clearance as a Class 2 device.
Healthy.io de Dip.io, a home-based urinalysis kit that turns a smartphone into a clinical-grade diagnostic device. It’s the first smartphone-based urine test to secure clearance as a Class 2 device.
12
Country: USA | Funding: $185.2M
Arthrosi Therapeutics is a biotechnology company that focuses on drug discovery and development.
Arthrosi Therapeutics is a biotechnology company that focuses on drug discovery and development.
13
Country: UK | Funding: £125M
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
14
Country: USA | Funding: $125.4M
Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines for infectious and non-infectious diseases.
Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines for infectious and non-infectious diseases.
15
Country: UK | Funding: $106.7M
RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease.
RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease.
16
Country: USA | Funding: $100M
Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases.
Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases.
17
Country: Singapore | Funding: $77.2M
AWAK develops wearable dialysis machines that operate and function like a normal kidney, for continuous dialysis.
AWAK develops wearable dialysis machines that operate and function like a normal kidney, for continuous dialysis.
18
Country: USA | Funding: $51M
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
19
Country: Kenya | Funding: $25M
Africa Healthcare Network is the first and largest dialysis chain across Sub-Saharan Africa, providing high-quality dialysis at an affordable cost.
Africa Healthcare Network is the first and largest dialysis chain across Sub-Saharan Africa, providing high-quality dialysis at an affordable cost.
20
Country: Germany | Funding: €21M
ADVOS is the world’s first method for the combined multi-organ support of liver, lung, kidney, and acid-base balance. Based on the principle of albumin dialysis, ADVOS allows extracorporeal fluid-based elimination of CO2, hepatic toxins, water-soluble and protein-bound nephrotoxins, as well as the correction of metabolic and respiratory acidosis. The ADVOS method works with typical dialysis accesses and flow rates and does not require any gas exchangers for CO2 elimination.
ADVOS is the world’s first method for the combined multi-organ support of liver, lung, kidney, and acid-base balance. Based on the principle of albumin dialysis, ADVOS allows extracorporeal fluid-based elimination of CO2, hepatic toxins, water-soluble and protein-bound nephrotoxins, as well as the correction of metabolic and respiratory acidosis. The ADVOS method works with typical dialysis accesses and flow rates and does not require any gas exchangers for CO2 elimination.
21
Country: USA | Funding: $7.1M
Early is Good (EIG) is leading the way in early detection and diagnosis of renal disease. With its innovative approach of assessing specific biomarkers found in urine, EIG is empowering patients and healthcare providers with the tools they need to detect and treat renal diseases such as bladder, kidney, and prostate cancer at an early stage. With the support of Social Capital, a Silicon Valley-based technology investment firm, EIG is well positioned to revolutionize the diagnostic industry and bring hope to millions of patients around the world.
Early is Good (EIG) is leading the way in early detection and diagnosis of renal disease. With its innovative approach of assessing specific biomarkers found in urine, EIG is empowering patients and healthcare providers with the tools they need to detect and treat renal diseases such as bladder, kidney, and prostate cancer at an early stage. With the support of Social Capital, a Silicon Valley-based technology investment firm, EIG is well positioned to revolutionize the diagnostic industry and bring hope to millions of patients around the world.
22
Country: USA | Funding: $4.6M
Helex is revolutionizing genomic medicine and advances in treating genetic kidney diseases. It designed lipid nanoparticle technology for targeted drug delivery and an intelligent drug design platform that enables de-risked, scalable and affordable therapeutics. Therapeutic payloads are directed to specific organs and cells beyond the liver filter. The technology is said to minimize immune response and eliminate the risk of insertional mutagenesis linked with viral vectors. Also it has greater scalability than viral vectors due to their simpler production process.
Helex is revolutionizing genomic medicine and advances in treating genetic kidney diseases. It designed lipid nanoparticle technology for targeted drug delivery and an intelligent drug design platform that enables de-risked, scalable and affordable therapeutics. Therapeutic payloads are directed to specific organs and cells beyond the liver filter. The technology is said to minimize immune response and eliminate the risk of insertional mutagenesis linked with viral vectors. Also it has greater scalability than viral vectors due to their simpler production process.
23
Country: France | Funding: €2.3M
Metyos is a biosensor that can monitor the effects of your daily activities.
Metyos is a biosensor that can monitor the effects of your daily activities.
24
Country: USA
NuVascular Technologies, Inc. is developing the next-generation of medical devices that will specifically treat patients suffering from end-stage renal (kidney) disease with the goal of helping patients live better and longer lives.
NuVascular Technologies, Inc. is developing the next-generation of medical devices that will specifically treat patients suffering from end-stage renal (kidney) disease with the goal of helping patients live better and longer lives.
25
Country: Israel | Funding: $1.5M
Serenno Medical is a medical device company creating a urine-output measuring device for the ICU.
Serenno Medical is a medical device company creating a urine-output measuring device for the ICU.
26
Country: USA | Funding: $20K
Nephrogen is a biotech company developing curative gene therapies for kidney diseases.
Nephrogen is a biotech company developing curative gene therapies for kidney diseases.
